Comment from Racquel Stucky
AnonymousSupportIndividual
Summary: A practicing family medicine and obstetrics physician from rural Kansas argues that the risks of Mifepristone may be higher than currently reported. The commenter supports maintaining REMS safeguards until more comprehensive data on serious side effects is available to ensure patient safety.
I am a practicing FM/OB in rural Kansas. With Mifepristone, there are questions about the true risks. While some say it is 0.65%, the numbers in Europe raise concerns it is higher like the 7.3% in Sweden. And the recent EPPC study, despite its weaknesses, raises concerns that we are missing data on the true incidence of serious side effects. Having REMS safeguards until we have better data to ensure we’re protecting women is not only reasonable but the right thing to do for our patients, so that we can all be fully informed.